ANTICANCER TUMOR CISPLATIN COMPOSITION WITH 6-PHOSPHOGLUCONATE DEHYDROGENASE INHIBITOR Russian patent published in 2019 - IPC A61K31/122 A61K31/282 A61K47/14 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents an anticancer composition consisting of cisplatin and Physcion 6-phosphogluconate dehydrogenase inhibitor, characterized in that it further contains an ethyl acetate solvent in ratios of: icisplatin 1–128 mcM: Physcion 25 mcM: ethyl acetate 0.5 %; cisplatin 1–128 mcM: Physcion 50 mcM: ethyl acetate 1 %; cisplatin 1–128 mcM: Physcion 150 mcM: ethyl acetate 3 %, with the possibility of increasing the sensitivity of the tumor cell line of lung carcinoma to 2.2 times and the tumor cell line of pancreatic cancer to 1.6 times as compared to the cisplatin monotherapy.

EFFECT: invention enables to obtain an anti-tumor cisplatin composition with a Physcion inhibitor dissolved in a neutral for tumor cells solvent ethyl acetate, which does not contain toxic components at all stages of its formation and without using additional complex expensive equipment.

1 cl, 3 dwg, 1 tbl